REFRACTORY FUNGAL VAGINITIS TREATED BY TOPICAL AMPHOTERICIN B. Review
Article PDF

Keywords

fungal vaginitis, antifungal drugs, topical Amphotericin B, Amphotericin B formula

Abstract views: 25
PDF Downloads: 1

How to Cite

Falah Hasan Obayes AL-Khikani. (2020). REFRACTORY FUNGAL VAGINITIS TREATED BY TOPICAL AMPHOTERICIN B. Review . Medical Science of Ukraine (MSU), 16(2), 55-58. https://doi.org/10.32345/2664-4738.2.2020.10

Abstract

Vaginitis is a common problem for women regarding a worldwide health challenge with many side effects. Vaginitis is among the most visiting to gynecology clinics. About 75% of all reproductive women had at least one fungal vaginitis infection in their life, and more than 40% will have two or more than two.  Candida spp is the most prevalent in fungal vaginitis, while reports for unusual fungi were observed as mucor spp.

Amphotericin B (AmB) belongs to the polyene group has a wide spectrum in vitro and in vivo antifungal activity. All of the known available formulas of AmB are administrated via intravenous injection to treat severe systemic fungal infections, while the development of the topical formula of AmB is still under preliminary development including topical vaginal AmB.

Due to the revealing of antimicrobial-resistant fungi in recent years, this study explains the role of topical AmB in treating refractory fungi vaginitis that may not a response to other drugs reported in many cases that may help researchers to develop new effective formula of AmB regarding fungal vaginitis.

https://doi.org/10.32345/2664-4738.2.2020.10
Article PDF

References

1. Kimberly A Workowski, Stuart Berman. Sexually transmitted diseases treatment guidelines. Centers for Disease Control and Prevention (CDC). 2015; 64: 1-137. Access mode: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm
2. Karaer A., Boylu M., Avsar A.F. Vaginitis in Turkish women: symptoms, epidemiologic-microbiologic association // Eur J Obstet Gynecol Reprod Biol. 2005; 121: 211-5. doi: 10.1016/j.ejogrb.2004.11.030. PMID: 16054964
3. Karasz A., Anderson M. The vaginitis monologues: women's experiences of vaginal complaints in a primary care setting // Soc Sci Med. 2003; 56 (5): 1013-21. doi: 10.1016/s0277-9536(02)00092-8. PMID: 12593874.
4. AL-Khikani F.H., AL-Janabi A.A. Topical Amphotericin B formulas: Promising new application // International Journal of Medical Science and Current Research. 2019; 2: 187-96. Access mode: http://www.ijmscr.com/issue/archive
5. Lanternier F., Lortholary O. Liposomal amphotericin B: what is its role in 2008? // Clinical Microbiology and Infection. 2008; 14 (4): 71-83. DOI: 10.1111/j.1469-0691.2008.01984.x
6. Scorzoni L., de Paula E. Silva A.C., Marcos C.M., Assato P.A., de Melo W.C., de Oliveira H.C., Costa-Oriandi C.B., Mendes-Giannini M.J., and Fusco-Almeida A.M. Antifungal therapy: new advances in the understanding and treatment of mycosis // Frontiers in Microbiology. 2017; 8: 1-23. https://doi.org/10.3389/fmicb.2017.00036
7. Crawford F., and Hollis S. Topical treatments for fungal infections of the skin and nails of the foot // Cochrane Database of Systematic Reviews. 2007; 3: CD001434. doi: 10.1002/14651858.CD001434.pub2.
8. Hay R. Therapy of skin, hair and nail fungal infections // Journal of Fungi. 2018; 4 (3): 99. https://dx.doi.org/10.3390%2Fjof4030099
9. Pendleton, R. A., and Holmes IV, J. H. Systemic absorption of amphotericin B with topical 5 % mafenide acetate/amphotericin B solution for grafted burn wounds: Is it clinically relevant? // Burns. 2010; 36 (1): 38-41. https://doi.org/10.1016/j.burns.2009.04.009
10. Phillips A.J. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories // American journal of obstetrics and gynecology. 2005; 192 (6): 2009-12. https://doi.org/10.1016/j.ajog.2005.03.034
11. Chamorro-de-Vega E., Gil-Navarro M.V., Perez-Blanco J.L. Treatment of refractory Candida krusei vaginitis with topical amphotericin B // Medicina clinica. 2016; 147 (12): 565-6. doi: 10.1016/j.medcli.2016.06.029.
12. Sobel J.D. Vaginal mucormycosis: a case report // Infectious diseases in obstetrics and gynecology. 2001; 9: 117-8. doi: 10.1155/S1064744901000205.
13. White D.J., Habib A.R., Vanthuyne A., Langford S., Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections // Sexually transmitted infections. 2001; 77 (3): 212-3. https://doi.org/10.1136/sti.77.3.212
14. Shann S., Wilson J. Treatment of Candida glabrata using topical amphotericin B and flucytosine // Sexually transmitted infections 2003; 79 (3): 265-6. https://doi.org/10.1136/sti.79.3.265-a
15. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. Atlanta (GA): U.S. Department of Health and Human Services; 2015. Access mode: https://wonder.cdc.gov/wonder/help/STD/STDSurv2014.pdf
16. Centers for Disease Control and Prevention. Genital/vulvovaginal candidiasis statistics. Retrieved March 27, 2012. Available from: http://www.cdc.gov/disease/candidiasis/genital/statistics.html)
17. Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by non-albicans Candida species: new insights // Curr Infect Dis Rep. 2010; 12(6): 465-70. https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.1007%2Fs11908-010-0137-9
18. Gaydos CA, Beqaj S, Schwebke JR, Lebed J, Smith B, Davis TE, Fife KH, Nyirjesy P, Spurrell T, Furgerson D, Coleman J. Clinical validation of a test for the diagnosis of vaginitis // Obstetrics and gynecology. 2017; 130 (1): 181. https://dx.doi.org/10.1097%2FAOG.0000000000002090
19. Bradford LL, Ravel J. The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases // Virulence. 2017; 8 (3): 342-51. doi: 10.1080/21505594.2016.1237332.
20. Morand, K., Bartoletti, A. C., Bochot, A., Barratt, G., Brandely, M. L., and Chast, F. Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability // International Journal of Pharmaceutics; 2007; 344 (1-2): 150-3. doi: 10.1016/j.ijpharm.2007.04.028.
21. Trasmonte M.V., Jiménez J.D., Santiago M.Á., Gálvez E., Jerez V., Pérez D., and Rubio J. A. Association of topical amphotericin B lipid complex treatment to standard therapy for rhinomaxillary mucormycosis after liver transplantation: a case report // In Transplantation Proceedings. 2012; 44 (7): 2120-3. doi: 10.1016/j.transproceed.2012.07.081
22. Sanchez D.A., Schairer D., Tuckman-Vernon C., Chouake J., Kutner A., Makdisi J., Friedman J.M., Nosanchuk J.D. and Friedman A.J. Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound // Nanomedicine: Nanotechnology, Biology and Medicine. 2014; 10 (1): 269-77. doi: 10.1016/j.nano.2013.06.002.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.